Table 3.

Dose modification of study drugs according to AEs

	IX (n=111)	X (n=100)
Dose reduction	61 (54.9)	34 (34.0)
Hematologic AE	52 (85.2)	9 (26.5)
Hand-foot syndrome	12 (23.1)	17 (50.0)
Diarrhea	4 (6.6)	0
Dose interruption	38 (34.2)	25 (25.0)
Hematologic AE	27 (71.1)	14 (56.0)
Hand-foot syndrome	5 (13.2)	7 (28.0)
Neutropenic fever	1 (2.6)	1 (4.0)
Diarrhea	1 (2.6)	1 (4.0)
Treatment discontinuation	1 (0.9)	3 (3.0)
	1 (arrhythmia)	1 (infection), 2 (hematologic AE)

Values are presented as number (%). AE, adverse events; IX, irinotecan and capecitabine combination; X, capecitabine alone.